Daniel Laheru
Overview
Explore the profile of Daniel Laheru including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
92
Citations
7753
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sinan H, Cunningham D, Sleiman E, Petry D, McPhaul T, Visvanathan K, et al.
JCO Precis Oncol
. 2025 Feb;
9:e2400494.
PMID: 39938008
Purpose: Current guidelines recommend offering genetic susceptibility testing to individuals with pancreatic cancer regardless of family history, but previous studies have reported only moderate test uptake, highlighting the need for...
2.
Madani S, Mohseni A, Mirza-Aghazadeh-Attari M, Shahbazian H, Afyouni S, Borhani A, et al.
Clin Imaging
. 2024 Nov;
117:110365.
PMID: 39613522
Purpose: To assess the utility of volumetric tumor enhancement on CT to predict tumor treatment response and the overall survival (OS) of patients with PDAC undergoing FOLFIRINOX-based systemic chemotherapy. Additionally,...
3.
Madani S, Mirza-Aghazadeh-Attari M, Mohseni A, Afyouni S, Zandieh G, Shahbazian H, et al.
J Gastrointest Surg
. 2024 Nov;
29(2):101882.
PMID: 39528002
Purpose: This study aimed to determine the value of radiomics features derived from baseline computed tomography (CT) scans and volumetric measurements to predict overall survival (OS) in patients with nonsurgical...
4.
Shu D, Ho W, Kagohara L, Girgis A, Shin S, Danilova L, et al.
Nat Immunol
. 2024 Oct;
25(11):2110-2123.
PMID: 39455893
Tertiary lymphoid structures (TLS) are associated with improved response in solid tumors treated with immune checkpoint blockade, but understanding of the prognostic and predictive value of TLS and the circumstances...
5.
Kung H, Shubert C, Wilbur C, Burns W, Burkhart R, Hidalgo M, et al.
J Gastrointest Surg
. 2024 Oct;
28(12):2031-2038.
PMID: 39368646
Background: Improved surgical techniques and more intensive systemic therapy have increased the number of patients with oligometastatic colorectal cancer eligible for resection, but a significant percentage of these cases will...
6.
Gupta A, De Jesus-Acosta A, Le D, Pishvaian M, Zaidi N, Zheng L, et al.
Cancer
. 2024 Jul;
130(21):3734-3744.
PMID: 38985839
Background: Pivotal clinical trials supported survival benefits of liposomal irinotecan (nal-IRI) plus fluorouracil/leucovorin in patients with pancreatic ductal adenocarcinoma (PDAC) who previously received gemcitabine-based therapy. There are concerns about the...
7.
Shu D, Ho W, Kagohara L, Girgis A, Shin S, Danilova L, et al.
bioRxiv
. 2023 Oct;
PMID: 37904980
Neoadjuvant immunotherapy is thought to produce long-term remissions through induction of antitumor immune responses before removal of the primary tumor. Tertiary lymphoid structures (TLS), germinal center-like structures that can arise...
8.
Kanbour S, Yenokyan G, Abusamaan M, Laheru D, Alam A, Asmar M, et al.
Pancreas
. 2023 Oct;
52(6):e309-e314.
PMID: 37890159
Background: Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis. Identifying modifiable risk factors, such as diabetes, is crucial. In the context of PDAC diagnosis, diabetes manifests as long-term (LTD), new-onset...
9.
Gupta A, De Jesus-Acosta A, Zheng L, Lee V, Kamel I, Le D, et al.
Front Oncol
. 2023 Sep;
13:1250136.
PMID: 37700832
Background: The efficacy of combination chemotherapy beyond the first-line setting remains modest in patients with advanced pancreatic adenocarcinoma (PAC). Evidence from recent clinical studies has shown that liposomal irinotecan (nal-IRI)...
10.
Heumann T, Judkins C, Li K, Lim S, Hoare J, Parkinson R, et al.
Nat Commun
. 2023 Jun;
14(1):3650.
PMID: 37339979
A neoadjuvant immunotherapy platform clinical trial allows for rapid evaluation of treatment-related changes in tumors and identifying targets to optimize treatment responses. We enrolled patients with resectable pancreatic adenocarcinoma into...